Distribution of lovastatin to bone and its effect on bone turnover in rats

Journal of Pharmacy and Pharmacology

Volumn 58, Issue 11, 2006, Pages 1451-1458

  Jadhav, Satyawan B ^a   Murthy, P S Narayana ^a   Singh, M M ^a   Jain, G K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 HYDROXYETHYL) 1 PIPERAZINEETHANESULFONIC ACID; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CHOLESTEROL; DEOXYPYRIDINOLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVASTATIN ACID; MEVINOLIN; PARATHYROID HORMONE; PLACEBO; PYRIDINOLINE; RALOXIFENE; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BONE METABOLISM; BONE TURNOVER; CHICK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS LINKING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; EMBRYO; FEMALE; HORMONE INHIBITION; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; RAT;

ADMINISTRATION, ORAL; ALKALINE PHOSPHATASE; AMINO ACIDS; ANIMALS; AREA UNDER CURVE; BONE RESORPTION; CARBON RADIOISOTOPES; CHICK EMBRYO; CHOLESTEROL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INJECTIONS, INTRAVENOUS; LIVER; LOVASTATIN; OVARIECTOMY; PARATHYROID HORMONE; RATS; RATS, SPRAGUE-DAWLEY; TIBIA; TIME FACTORS; TISSUE DISTRIBUTION; WEIGHT GAIN;

EID: 33751256268     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.58.11.0005     Document Type: Article

References (37)

1. Arshad, M., Sengupta, S., Sharma, S., Ghosh, R., Sawlani, V., Singh, M. M. (2004) In vitro anti-resorptive activity and prevention of ovariectomy-induced osteoporosis in female Sprague-Dawley rats by ormeloxifene, a selective estrogen receptor modulator. J. Steroid Biochem. Mol. Biol. 91: 67-78
2. Baumann, A. P., Grasser, W., Petras, S., Harwood, H., Thompson, D. D., Paralkar, V. (2001) Inhibition of osteoclast formation by statins. J. Bone Miner. Res. 16: S507
3. Baylink, D. J., Strong, D. D., Mohan, S. (1999) The diagnosis and treatment of osteoporosis: future prospects. Mol. Med. 5: 133-140
4. Benford, H. L., Frith, J. C., Auriola, S., Monkkonen, J., Rogers, M. J. (1999) Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates; biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol. Pharmacol. 56: 131-140
5. Black, D., Duncan, A., Robins, S. P. (1988) Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reverse-phase high performance liquid chromatography. Anal. Biochem. 169: 197-203
6. Corsino, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., Bernini, F. (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84: 413-428
7. Crawford, D. T., Qi, H., Chidsey-Frink, K. L., Simmons, H. A., Thomson, D. D., Ke, H. Z. (2001) Statin increases cortical bone in young male rats by single, local administration but fails to restore bone in ovariectomized (OVX) rats by daily systemic administration. J. Bone Miner. Res. 16: S295
8. Dempster, D. W., Birchman, R., Xu, R., Lindsay, R., Shen, V. (1995) Temporal changes in cancellous bone structure of rats immediately after ovariectomy. Bone 16: 157-161
9. Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., Rojers, M. J. (2001) Structure-activity relationship for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296: 235-242
10. Fisher, J. E., Rojers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G., Rodan, G. A., Reszka, A. A. (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc. Natl Acad. Sci. USA 96: 133-138
11. Germershausen, J. I., Vincent, M. H., Bostedor, R. G., Bailey, P. J., Karkas, J. D., Alberts, A. W. (1989) Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem. Biophys. Res. Commun. 158: 667-675
12. Gutierrez, G., Garrett, J. R., Rossini, G., Castano, M., Chapa, G., Escobedo, J., Esparza, A., Horn, D., Qiao, M., Taylor, S., Lalka, D., Mundy, G. R. (2000) Dermal application of lovastatin to rats causes greater increases in bone formation and plasma concentrations than when administered by oral gavage. J. Bone Miner Res. 15: S427
13. Gutierrez, G., Garrett, J. R., Rossini, G., Escobedo, A., Horn, D., Qiao, M., Esparza, J., Lalka, D., Mundy, G. R. (2001) Dermal application of lovastatin for 5 days stimulates bone formation in ovariectomized rats by 160%. J. Bone Miner. Res. 16: S222
14. Jadhav, S. B., Jain, G. K. (2006) Statins and osteoporosis: new role for old drugs. J. Pharm. Pharmacol. 58: 3-18
15. Kleinsek, D. A., Duggan, R. E., Baker, T. A., Porter, J. W. (1981) 3-Hydroxy-3-methylglutaryl-CoA reductase from rat liver. Methods Enzymol. 71: 462-479
16. LaRosa, J. C., He, J., Vupputuri, S. (1999) Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282: 2340-2346
17. Lilja, J. J., Kivisto, K. T., Neuvonen, P. J. (1998) Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther. 64: 477-483
18. Liu, L., Zhang, R., Zhao, J. J., Rogers, J. D., Hsieh, J. Y. K., Fang, W., Matuszewski, B. K., Dobrinska, M. R. (2003) Determination of simvastatin-derived HMG-CoA reductase inhibitors in biomatrices using an automated enzyme inhibition assay with radioactive detection. J. Pharm. Biomed. Anal. 32: 107-123
19. Luckman, S. P., Hughes, D. E., Coxon, F. P., Graham, R., Russell, G., Rogers, M. J. (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13: 581-589
20. Maeda, T., Matsunuma, A., Kawane, T., Horiuchi, N. (2001) Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 280: 874-877
21. Maritz, F. J., Conradie, M. M., Hulley, P. A., Gopal, R., Hough, S. (2001) Effect of statins on bone mineral density and bone histomorphometry in rodents Arterioscler. Thromb. Vasc. Biol. 21: 1636-1641
22. Meier, C. R., Schlienger, R. G., Kraenzlin, M. E., Schlegel, B., Jick, H. (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283: 3205-3210
23. Meunier, P. J. (2001) Anabolic agents for treating postmenopausal osteoporosis. Joint Bone Spine 68: 576-581
24. Mundy, G. R. (2001) Statins and their potential for osteoporosis. Bone 29: 495-497
25. Mundy, G., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B., Zhao, M., Gutierrez, G. (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946-1949
26. Oxlund, H., Andreassen, T. T. (2004) Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone 34: 609-618
27. Oxlund, H., Dalstra, M., Andreassen, T. T. (2001) Statin given per orally to adult rats increases cancellous bone mass and compressive strength. Calcif. Tissue Int. 69: 299-304
28. Reinoso, R. F., SanchezNavarro, A., Garcia, M. J., Prous, J. R. (2002) Preclinical pharmacokinetics of statins. Methods Find. Clin. Pharmacol. 24: 593-613
29. Rejnmark, L., Olsen, M. L., Johnsen, P., Vestergaard, P., Sorensen, H. T., Mosekilde, L. (2004) Hip fracture risk in statin users-a population-based Danish case-control study. Osteoporos. Int. 15: 452-458
30. Rosen, C. J., Bilezikian, J. P. (2001) Clinical review 123: hot topic anabolic therapy for osteoporosis. J. Clin. Endocrinol. Metab. 86: 957-964
31. Sengupta, S., Arshad, M., Sharma, S., Dubey, M., Singh, M. M. (2005) Attainment of peak bone mass and bone turnover rate in relation to estrous cycle, pregnancy and lactation in colony-bred Sprague-Dawley rats: suitability for studies on pathophysiology of bone and therapeutic measures for its management. J. Steroid Biochem. Mol. Biol. 94: 421-429
32. Staal, A., Frith, J. C., French, M. H., Swartz, J., Gungor, T., Harrity, T. W., Tamasi, J., Rogers, M. J., Feyen, J. H. (2003) The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J. Bone Miner Res. 18: 88-96
33. Sugiyama, M., Kodama, T., Konishi, K., Abe, K., Asami, S., Oikawa, S. (2000) Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun. 271: 688-692
34. van Beek, E., Lowik, C., van der Pluijm, G., Papapoulos, S. (1999) The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen containing bisphosphonates. J. Bone Miner. Res. 14: 722-729
35. van Staa, T. P., Wegman, S., de Vries, F., Leufkens, B., Cooper, C. (2001) Use of statins and risk of fractures. JAMA 285: 1850-1855
36. von Stechow, D., Fish, S., Yahalom, D., Bab, I., Chorev, M., Muller, R., Alexander, J. M. (2003) Does simvastatin stimulate bone formation in vivo? BMC Musculoskelet. Disord. 4: 8
37. Wang, P. S., Solomon, D. H., Mogun, H., Avorn, J. (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283: 3211-3216